Latest & greatest articles for alzheimer's disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer's disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer's disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alzheimer's disease

1. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials (Full text)

Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) Psychiatry Actions . 2020 Jul 20;jnnp-2019-321913. doi: 10.1136/jnnp-2019-321913. Online ahead of print. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials # , # , # , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China jintai_yu

2020 EvidenceUpdates PubMed abstract

2. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. (Abstract)

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. There are limitations in current diagnostic testing approaches for Alzheimer disease (AD).To examine plasma tau phosphorylated at threonine 217 (P-tau217) as a diagnostic biomarker for AD.Three cross-sectional cohorts: an Arizona-based neuropathology cohort (cohort 1), including 34 participants with AD and 47 without AD (dates of enrollment, May 2007-January 2019); the Swedish BioFINDER (...) -2 cohort (cohort 2), including cognitively unimpaired participants (n = 301) and clinically diagnosed patients with mild cognitive impairment (MCI) (n = 178), AD dementia (n = 121), and other neurodegenerative diseases (n = 99) (April 2017-September 2019); and a Colombian autosomal-dominant AD kindred (cohort 3), including 365 PSEN1 E280A mutation carriers and 257 mutation noncarriers (December 2013-February 2017).Plasma P-tau217.Primary outcome was the discriminative accuracy of plasma P-tau217

2020 JAMA

3. Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial (Full text)

in beta-amyloid protein–infused rats. J Neurochem. 1996;66(3):1113-1117. doi:10.1046/j.1471-4159.1996.66031113.x - - Joyce JN, Smutzer G, Whitty CJ, Myers A, Bannon MJ. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson’s, Alzheimer’s with parkinsonism, and Alzheimer’s disease. Mov Disord. 1997;12(6):885-897. doi:10.1002/mds.870120609 - - Pan X, Kaminga AC, Wen SW, Wu X, Acheampong K, Liu A. Dopamine and dopamine receptors (...) Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID

2020 EvidenceUpdates PubMed abstract

4. Flortaucipir F18 (Tauvid) - Diagnostic agent for patients with Alzheimer’s disease

Flortaucipir F18 (Tauvid) - Diagnostic agent for patients with Alzheimer’s disease Drug Approval Package: TAUVID U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: TAUVID Company: Avid Radiopharmaceuticals, Inc. Application Number: 212123 Approval Date: 05/28/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2020 FDA - Drug Approval Package

5. Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT (Full text)

Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Minocycline did not delay the progress of cognitive or functional impairment in people with mild Alzheimer's disease over 2 years and minocycline 400 mg was poorly tolerated. {{author}} {{($index , , , , , , , , , , , , , , , , , , , & . Robert Howard 1, * , Olga Zubko 2 , Richard Gray 3 , Rosie Bradley 4 , Emma Harper 4 , Linda Kelly 4 , Lynn Pank 4 , John O’Brien 5 , Chris Fox 6 , Naji Tabet 7 , Gill

2020 NIHR HTA programme PubMed abstract

6. Association between rs10046, rs1143704, rs767199, rs727479, rs1065778, rs1062033, rs1008805, and rs700519 polymorphisms in aromatase (CYP19A1) gene and Alzheimer's disease risk: a systematic review and meta-analysis involving 11,051 subjects. (Abstract)

Association between rs10046, rs1143704, rs767199, rs727479, rs1065778, rs1062033, rs1008805, and rs700519 polymorphisms in aromatase (CYP19A1) gene and Alzheimer's disease risk: a systematic review and meta-analysis involving 11,051 subjects. CYP19A1 enzyme (aromatase) encoded by CYP19A1 (cytochrome p450 family 19 subfamily a member 1) gene plays a key role in the biosynthesis of estrogen, which has been significantly associated with Alzheimer's disease (AD). To ascertain whether CYP19A1 gene

2020 Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

7. An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. (Full text)

An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations. Parietal cortex RNA-sequencing (RNA-seq) data were generated from individuals with and without Alzheimer disease (AD; ncontrol = 13; nAD = 83) from the Knight Alzheimer Disease Research Center (Knight ADRC). Using this and an independent (Mount Sinai Brain Bank (MSBB)) AD RNA-seq dataset, cortical circular RNA (circRNA) expression was quantified in the context of AD

2020 Nature neuroscience PubMed abstract

8. A systematic review on anti-Alzheimer's disease activity of prescription Kangen-karyu. (Full text)

A systematic review on anti-Alzheimer's disease activity of prescription Kangen-karyu. Traditional Chinese and Japanese medicines have become prime sources of drug discovery and there is a pressing need to investigate the effectiveness of these traditional medicines for modern drug discovery. Recently, among various traditional formulations, studies on Kangen-karyu (Guan-Yuan-Ke-Li), a mixture of six medicinal herbs (Salviae Miltiorrhizae Radix, Cnidii Rhizoma, Paeoniae Radix, Carthami Flos (...) , Aucklandiae Radix, and Cyperi Rhizoma), have been growing to assess its neuroprotective role. This prompted us to undertake a thorough review of various targets of Kangen-karyu regarding its effectiveness against Alzheimer's disease, particularly focusing on cholinesterases, beta-site amyloid precursor protein cleaving enzyme 1, and glycogen synthase kinase 3β. This review provides new insights into Kangen-karyu medication as a prospective anti-Alzheimer's medication and indicates the need for in-depth

2020 Drug discoveries & therapeutics PubMed abstract

9. Verum- versus Sham-Acupuncture on Alzheimer's Disease (AD) in Animal Models: A Preclinical Systematic Review and Meta-Analysis. (Full text)

Verum- versus Sham-Acupuncture on Alzheimer's Disease (AD) in Animal Models: A Preclinical Systematic Review and Meta-Analysis. Alzheimer's disease (AD) is a common health condition affecting senile people and leads to severe cognitive dysfunctions. Acupuncture has been shown to be a possible alternative natural remedy for AD in some animal studies.To perform a systematic review to identify the effect of verum-acupuncture compared with sham-acupuncture on learning and memory performance among

2020 BioMed research international PubMed abstract

10. Epidemiology of Alzheimer's Disease and Dementia in Arab Countries: A Systematic Review. (Full text)

Epidemiology of Alzheimer's Disease and Dementia in Arab Countries: A Systematic Review. Contrary to popular belief, the condition of dementia is not an actual discrete disease, but rather a group of symptoms, most notable of which is the disturbance of memory and social ability, often severe enough to impair daily functioning. As a result, it has been a major cause of functional deterioration among varying populations in the world. This study is aimed at reviewing the epidemiology of dementia (...) in Arab countries in terms of its prevalence, distribution, and risk factors.A systematic literature review was conducted using articles published in PubMed, Embase, Scopus, and other local journals between 1990 and 2018. After applying the inclusion and exclusion criteria, a total of 18 studies were concluded to be eligible for the review.Prevalence studies demonstrated that dementia is indeed a prevalent condition in Arab countries, ranging between 1.1% and 2.3% among age groups of 50 years

2020 Behavioural neurology PubMed abstract

11. Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia: A Systematic Review. (Abstract)

Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia: A Systematic Review. Biomarker accuracy for Alzheimer disease (AD) is uncertain.To summarize evidence on biomarker accuracy for classifying AD in older adults with dementia.Electronic bibliographic databases (searched from January 2012 to November 2019 for brain imaging and cerebrospinal fluid [CSF] tests and from inception to November 2019 for blood tests), ClinicalTrials.gov

2020 Annals of Internal Medicine

12. From Polygenic Scores to Precision Medicine in Alzheimer's Disease: A Systematic Review. (Full text)

From Polygenic Scores to Precision Medicine in Alzheimer's Disease: A Systematic Review. Late-onset Alzheimer's disease (AD) is highly heritable. The effect of many common genetic variants, single nucleotide polymorphisms (SNPs), confer risk. Variants are clustered in areas of biology, notably immunity and inflammation, cholesterol metabolism, endocytosis, and ubiquitination. Polygenic scores (PRS), which weight the sum of an individual's risk alleles, have been used to draw inferences about (...) and phenotypic changes may allow us to define the biology of the disease in individuals and indicate who may benefit from specific treatments. Longitudinal cohort studies are required to test the ability of PGS to delineate pathway-specific disease activity.

2020 Journal of Alzheimer's disease : JAD PubMed abstract

13. Fluid Biomarkers and APOE Status of Early Onset Alzheimer's Disease Variants: A Systematic Review and Meta-Analysis. (Abstract)

Fluid Biomarkers and APOE Status of Early Onset Alzheimer's Disease Variants: A Systematic Review and Meta-Analysis. Numerous studies have reported on cerebrospinal fluid (CSF) and blood biomarkers of Alzheimer's disease (AD); however, to date, none has compared biomarker patterns across the early-onset subtypes, i.e., early onset sporadic AD (EOsAD) and autosomal dominant AD (ADAD), qualitatively and quantitatively.To compare the fluid biomarker patterns in early-onset subtypes of AD; EOsAD

2020 Journal of Alzheimer's disease : JAD

14. Blood fatty acids in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review. (Abstract)

Blood fatty acids in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review. Plasma fatty acids have been reported to be dysregulated in mild cognitive impairment (MCI) and Alzheimer's disease (AD), though outcomes are not always consistent, and subject numbers often small. Our aim was to use a meta-analysis and systematic review approach to identify if plasma fatty acid dysregulation would be observed in case control studies of AD and MCI. Six databases were

2020 Ageing research reviews

15. Association between atherosclerosis and Alzheimer's disease: A systematic review and meta-analysis. (Full text)

Association between atherosclerosis and Alzheimer's disease: A systematic review and meta-analysis. To evaluate the relationship between atherosclerosis and Alzheimer's disease (AD), we conducted a systematic review and meta-analysis to study the difference of carotid intima-media thickness (CIMT) and the prevalence of atherosclerosis between AD patients and non-AD controls.The studies on the association between atherosclerosis and AD were manually searched in PubMed, Embase, Cochrane Library

2020 Brain and behavior PubMed abstract

16. Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer's disease: a cumulative meta-analysis and trial sequential analysis. (Abstract)

Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer's disease: a cumulative meta-analysis and trial sequential analysis. To study the strength of the evidence on efficacy, safety and acceptability of cholinesterase inhibitors (ChEI) and memantine for Alzheimer's disease (AD); and to determine the number of redundant post-authorisation trials.A cumulative meta-analysis with a trial sequential analysis (TSA) was performed. Primary

2020 European journal of clinical pharmacology

17. Postmenopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease: A systematic review and time-response meta-analysis. (Abstract)

Postmenopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease: A systematic review and time-response meta-analysis. Hormone therapy continues to be a favourable option in the management of menopausal symptomatology, but the associated risk-benefit ratios with respect to neurodegenerative diseases remain controversial. The study aim was to determine the relation between menopausal hormone therapy and Alzheimer's disease, dementia, and Parkinson's disease in human (...) subjects. A literature search was performed in PubMed/Medline, Cochrane collaboration, and Scopus databases from onset of the database to September 2019. Random-effects model was used to estimate pooled odd ratio (OR) and 95 % confidence intervals (CI). Subgroup analysis was performed based on the type and formulation of hormone. In addition, the time-response effect of this relationship was also assessed based on duration of hormone therapy. Associations between hormone therapy and Alzheimer's disease

2020 Pharmacological Research

18. Traditional Chinese medicine Danggui Shaoyao San for the treatment of Alzheimer's disease: A Protocol for Systematic Review. (Full text)

to February 29, 2020. Randomized controlled trials (RCTs) that meet the pre-specified eligibility criteria will be included. RevMan software (V.5.3.5) will be used to perform data synthesis following data extraction and publication risk assessment. Subgroup and sensitivity analysis will be performed according to the condition of included RCTs. The primary outcomes include changes in the Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog), and Activities (...) Traditional Chinese medicine Danggui Shaoyao San for the treatment of Alzheimer's disease: A Protocol for Systematic Review. Alzheimer's disease (AD) is the most common cause of dementia. Traditional Chinese formula Danggui Shaoyao San (DSS) has been considered a potential therapeutic approach for AD. However, no systemic review regarding its efficacy and safety has been conducted. Herein, we propose a protocol for the study that aims to evaluate the efficacy and safety of DSS in patients

2020 Medicine PubMed abstract

19. Adjusted mortality rates attributable to Alzheimer's disease dementia, Brazil, 2009-2013. (Full text)

Adjusted mortality rates attributable to Alzheimer's disease dementia, Brazil, 2009-2013. This paper provides estimates of mortality rates from Alzheimer's disease dementia (AD) in the elderly Brazilian population. Data were obtained from the 2010 Population Census by Brazilian Institute of Geography and Statistics (IBGE) and microdata on mortality in Brazil's 27 state capitals recorded in the Brazilian Mortality Information System (SIM) for the population 65 years or older by place (...) of residence for the years 2009 to 2013. Corrections were obtained for underreporting of mortality, and final adjustments were made to the specific mortality rates based on Bayesian methods with prior probability distributions built on the basis of information obtained from a meta-analysis. The mortality rates from all dementias and from AD in Brazil were higher than in developed countries. The mortality rates from Alzheimer's disease in 2013 were 140.03 (95%CI: 117.05; 166.4) and 127.07 (95%CI: 103.74

2020 Cadernos de saude publica PubMed abstract

20. Transcranial Direct Current Stimulation Improves Cognitive Function in Mild to Moderate Alzheimer Disease: A Meta-Analysis. (Abstract)

Transcranial Direct Current Stimulation Improves Cognitive Function in Mild to Moderate Alzheimer Disease: A Meta-Analysis. The purpose of this meta-analysis was to evaluate the therapeutic effect of transcranial direct current stimulation (tDCS) on mild to moderate Alzheimer disease (AD) patients.PubMed, Embase, Web of Science, and Cochrane Library were searched until April 2018. The primary cognitive outcomes were extracted from included articles. A crude standardized mean difference with 95

2020 Alzheimer disease and associated disorders